Style | Citing Format |
---|---|
MLA | Didari E, et al.. "A Pharmacogenetic Pilot Study of Cyp2c9 Common Genetic Variant and Sulfonylureas Therapeutic Response in Type 2 Diabetes Mellitus Patients." Journal of Diabetes and Metabolic Disorders, vol. 20, no. 2, 2021, pp. 1513-1519. |
APA | Didari E, Sarhangi N, Afshari M, Aghaei Meybodi HR, Hasanzad M (2021). A Pharmacogenetic Pilot Study of Cyp2c9 Common Genetic Variant and Sulfonylureas Therapeutic Response in Type 2 Diabetes Mellitus Patients. Journal of Diabetes and Metabolic Disorders, 20(2), 1513-1519. |
Chicago | Didari E, Sarhangi N, Afshari M, Aghaei Meybodi HR, Hasanzad M. "A Pharmacogenetic Pilot Study of Cyp2c9 Common Genetic Variant and Sulfonylureas Therapeutic Response in Type 2 Diabetes Mellitus Patients." Journal of Diabetes and Metabolic Disorders 20, no. 2 (2021): 1513-1519. |
Harvard | Didari E et al. (2021) 'A Pharmacogenetic Pilot Study of Cyp2c9 Common Genetic Variant and Sulfonylureas Therapeutic Response in Type 2 Diabetes Mellitus Patients', Journal of Diabetes and Metabolic Disorders, 20(2), pp. 1513-1519. |
Vancouver | Didari E, Sarhangi N, Afshari M, Aghaei Meybodi HR, Hasanzad M. A Pharmacogenetic Pilot Study of Cyp2c9 Common Genetic Variant and Sulfonylureas Therapeutic Response in Type 2 Diabetes Mellitus Patients. Journal of Diabetes and Metabolic Disorders. 2021;20(2):1513-1519. |
BibTex | @article{ author = {Didari E and Sarhangi N and Afshari M and Aghaei Meybodi HR and Hasanzad M}, title = {A Pharmacogenetic Pilot Study of Cyp2c9 Common Genetic Variant and Sulfonylureas Therapeutic Response in Type 2 Diabetes Mellitus Patients}, journal = {Journal of Diabetes and Metabolic Disorders}, volume = {20}, number = {2}, pages = {1513-1519}, year = {2021} } |
RIS | TY - JOUR AU - Didari E AU - Sarhangi N AU - Afshari M AU - Aghaei Meybodi HR AU - Hasanzad M TI - A Pharmacogenetic Pilot Study of Cyp2c9 Common Genetic Variant and Sulfonylureas Therapeutic Response in Type 2 Diabetes Mellitus Patients JO - Journal of Diabetes and Metabolic Disorders VL - 20 IS - 2 SP - 1513 EP - 1519 PY - 2021 ER - |